Market Cap 153.00M
Revenue (ttm) 0.00
Net Income (ttm) -19.00M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 197,200
Avg Vol 81,784
Day's Range N/A - N/A
Shares Out 25.46M
Stochastic %K 75%
Beta -0.29
Analysts Strong Sell
Price Target $18.00

Company Profile

Nuvectis Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious conditions of unmet medical need in oncology. Its lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trial for the treatment of patients with platinum-resistant ARID1a-mutated ovarian carcinoma. The company is also developing NXP900, a small molecule drug candidate, which is in Phase 1a clinical trial that inhibits th...

Industry: Biotechnology
Sector: Healthcare
Phone: 201 614 3150
Address:
1 Bridge Plaza, Suite 275, Fort Lee, United States
Goodstockday
Goodstockday Oct. 23 at 6:42 PM
$NVCT The safety data looks strong on today’s poster. Next task is to evaluate efficacy.
0 · Reply
BioTrade2
BioTrade2 Oct. 18 at 2:14 AM
$NVCT watch this https://conferences-on-demand.faseb.org/do/10.1096/CCC2023.S09.P01/full/
1 · Reply
DARKP00L
DARKP00L Oct. 16 at 12:06 PM
$NVCT 08:02 on Oct. 16 2025 Nuvectis To Present NXP900 Clinical Safety And FAT1 Tumor Data At AACR-NCI-EORTC 2025 International Conference #tradeideas
0 · Reply
WallStWireAds
WallStWireAds Oct. 16 at 12:03 PM
$NVCT https://caplynx.io/2Iu1ZLe
0 · Reply
BioTrade2
BioTrade2 Oct. 14 at 4:01 PM
$NVCT anyone know when to expect any efficacy data from the ph1b trial? Feel like this we’ll keep bleeding slowly until then
1 · Reply
UNLV
UNLV Oct. 13 at 2:31 PM
$NVCT Truffle Pig and Jordan Alexander mentioned much when there was enthusiasm around here QURE the latest TP a slam dunk imo very much de-risked and won’t have competition
0 · Reply
buyandsold
buyandsold Oct. 9 at 7:14 PM
$NVCT bought more. It's 8x or bust.
0 · Reply
BioTrade2
BioTrade2 Oct. 9 at 1:54 AM
$NVCT I'm on a full-blown research mode https://pmc.ncbi.nlm.nih.gov/articles/PMC7611940/#:~:text=Significance:%20Small%20molecule%E2%80%93mediated%20inhibition%20of%20SRC%20impairing,and%20tolerability%20compared%20with%20other%20SRC/ABL%20inhibitors
1 · Reply
mmtiddy
mmtiddy Oct. 8 at 6:40 PM
$NVCT Hidden gem
0 · Reply
BioTrade2
BioTrade2 Oct. 8 at 1:43 PM
$NVCT saractinib was able to inhibit tumors but no confirmed PR or CR. https://aacrjournals.org/clincancerres/article/16/19/4876/75479/Phase-I-Safety-Pharmacokinetics-and-Inhibition-of
1 · Reply
Latest News on NVCT
Nuvectis Pharma to Present at the 36th Annual Roth Conference

Mar 15, 2024, 8:00 AM EDT - 1 year ago

Nuvectis Pharma to Present at the 36th Annual Roth Conference


Nuvectis: Early Stage Company That's Low On Cash

Sep 6, 2023, 8:03 AM EDT - 2 years ago

Nuvectis: Early Stage Company That's Low On Cash


Nuvectis Pharma Announces FDA Clearance of NXP900 IND

May 15, 2023, 8:00 AM EDT - 2 years ago

Nuvectis Pharma Announces FDA Clearance of NXP900 IND


Goodstockday
Goodstockday Oct. 23 at 6:42 PM
$NVCT The safety data looks strong on today’s poster. Next task is to evaluate efficacy.
0 · Reply
BioTrade2
BioTrade2 Oct. 18 at 2:14 AM
$NVCT watch this https://conferences-on-demand.faseb.org/do/10.1096/CCC2023.S09.P01/full/
1 · Reply
DARKP00L
DARKP00L Oct. 16 at 12:06 PM
$NVCT 08:02 on Oct. 16 2025 Nuvectis To Present NXP900 Clinical Safety And FAT1 Tumor Data At AACR-NCI-EORTC 2025 International Conference #tradeideas
0 · Reply
WallStWireAds
WallStWireAds Oct. 16 at 12:03 PM
$NVCT https://caplynx.io/2Iu1ZLe
0 · Reply
BioTrade2
BioTrade2 Oct. 14 at 4:01 PM
$NVCT anyone know when to expect any efficacy data from the ph1b trial? Feel like this we’ll keep bleeding slowly until then
1 · Reply
UNLV
UNLV Oct. 13 at 2:31 PM
$NVCT Truffle Pig and Jordan Alexander mentioned much when there was enthusiasm around here QURE the latest TP a slam dunk imo very much de-risked and won’t have competition
0 · Reply
buyandsold
buyandsold Oct. 9 at 7:14 PM
$NVCT bought more. It's 8x or bust.
0 · Reply
BioTrade2
BioTrade2 Oct. 9 at 1:54 AM
$NVCT I'm on a full-blown research mode https://pmc.ncbi.nlm.nih.gov/articles/PMC7611940/#:~:text=Significance:%20Small%20molecule%E2%80%93mediated%20inhibition%20of%20SRC%20impairing,and%20tolerability%20compared%20with%20other%20SRC/ABL%20inhibitors
1 · Reply
mmtiddy
mmtiddy Oct. 8 at 6:40 PM
$NVCT Hidden gem
0 · Reply
BioTrade2
BioTrade2 Oct. 8 at 1:43 PM
$NVCT saractinib was able to inhibit tumors but no confirmed PR or CR. https://aacrjournals.org/clincancerres/article/16/19/4876/75479/Phase-I-Safety-Pharmacokinetics-and-Inhibition-of
1 · Reply
RetracementRanger
RetracementRanger Oct. 5 at 2:51 PM
$NVCT Healthcare technology. Testing key support. Volume pattern shows distribution. Growth concerns persisting.
0 · Reply
mmtiddy
mmtiddy Oct. 2 at 10:57 AM
$NVCT Starting a small position, will add if it continues to drop, but seems well established at accumulation zone Catalysts for next year, cash runway till Q1 2027 Good insider purchases in the last 12 months
0 · Reply
BioTrade2
BioTrade2 Oct. 2 at 2:12 AM
$NVCT more reading https://aacrjournals.org/cancerres/article/81/21/5438/670511/A-Conformation-Selective-Mode-of-Inhibiting-SRC
1 · Reply
BioTrade2
BioTrade2 Oct. 1 at 6:23 PM
$NVCT read it. Understand it https://pubmed.ncbi.nlm.nih.gov/32466572/
0 · Reply
buyandsold
buyandsold Sep. 29 at 8:58 PM
$NVCT very cheap given they will cure cancer
0 · Reply
BioTrade2
BioTrade2 Sep. 26 at 1:07 AM
$NVCT IMRX PRQR XAIR What do these all have in common? We’re not in good company. Jordan had an amazing call on AXSM, but just about everything after that has been a dud.
2 · Reply
WallStWireAds
WallStWireAds Sep. 25 at 12:03 PM
$NVCT https://caplynx.io/CgvV3el
0 · Reply
essiepaul
essiepaul Sep. 24 at 2:45 PM
$NVCT welcome to tax loss season. Expecting $5’s from this gem unless they put out some decent news
1 · Reply
BioSensai
BioSensai Sep. 19 at 8:06 PM
$NVCT Guess who is back ;) Data likely will begin trickling in q2-26
2 · Reply
UNLV
UNLV Sep. 19 at 6:37 PM
$NVCT 1b expansion slated start later this year. Management huge shareholders and going all-in testing many/all indications in one trial High selectivity, high concentration during entire 24 hour dosing and no dose limiting toxicity
1 · Reply
UNLV
UNLV Sep. 17 at 5:29 PM
$NVCT looking at LOCATIONS finds all USA locations recruiting. UK locations completed trial. Let's remember insider Charles was buying big.....company knows UK results and UK research led early development Study Details | NCT05873686 | A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers | ClinicalTrials.gov https://share.google/qJq9pHRd6QvpAOtr9
1 · Reply
BioTrade2
BioTrade2 Sep. 16 at 6:55 PM
$NVCT what have they achieved over the last 4 years? Only started mono therapy 900 trial. That’s it. Have owned it since ‘22, nothing to show for it. Meanwhile so many companies in XBI skyrocketed. We’re always 6-9 months away from earth shattering data.
1 · Reply